← All trials
NCT04665362
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 28, 2020
- Primary completion
- Jun 1, 2022
- Completion date
- Oct 30, 2022
- First posted
- Dec 11, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversitySponsor investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- VirotechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.